NanoString Blog

Category: Oncology

Oncology

What is Comparative Oncology and Why Has it Gone to the Dogs?

Deciding which model system to use to answer biological questions is a critical choice in research. Many human diseases occur naturally or can be reproduced in animals. Depending on the…

Alicia Lane / May 2, 2023
Rendering of oncology proteins

Oncology

Five Key Milestones in the History of Research in Cancer Biology

On a cold snowy day in late November 2016, I sat with my father-in-law at the infusion clinic in the local hospital. I was visiting Pennsylvania for my mother-in-law’s funeral.…

Melanie Peffer / May 5, 2022
Rendering of oncology proteins

Digital Spatial Profiling GeoMx DSP nCounter Oncology Spatial Transcriptomics

New approaches to CAR-T therapy

What is CAR-T cell therapy? In the fight against cancer, immunotherapies that enlist and strengthen the power of a patient’s immune system to attack tumor cells have revolutionized treatment paradigms.…

Nirupama Deshpande / January 18, 2022

Immunology Infectious Disease Oncology Publication Watch

T-Cell Receptor Diversity…What Are You Missing?

The T cell receptor (TCR) is one of the distinguishing molecules of the adaptive immune system. TCRs allow mammalian immune systems to recognize and respond to foreign entities (pathogens, vaccines,…

Trena Cormier / November 15, 2021
Breast cancer rendering

GeoMx DSP Oncology

Breast Cancer: Best practices for using GeoMx® Digital Spatial Profiler

It’s October and breast cancer awareness month. Breast cancer kills more women than any other type of cancer. It isn’t just limited to women either – a man’s lifetime breast…

Melanie Peffer / October 15, 2021

Oncology Q&A

What is the Next Frontier in Cellular Therapy?

In early June 2021, NanoString and the Parker Institute for Cancer Immunotherapy (PICI) announced a multi-center collaboration to characterize 800 CAR-T samples in a unique and concerted effort to understand…

Laura Tabellini Pierre / July 26, 2021

Oncology Q&A

A “Tail” of Two Species: New Canine Immuno-Oncology Research Offering

NanoString has an unparalleled and longstanding tradition of developing best-in-class cancer research tools, thanks to an extensive knowledge accumulated in a decade of interrogating all aspects of the disease. Last…

Laura Tabellini Pierre / March 1, 2021

Clinical Research Infectious Disease Oncology

Of Mice and Men: The importance of Mouse Models in Research

Many animals share common biology with humans, are affected by similar diseases, and may have a comparable response to certain treatments. Animal models are thus useful to address scientific questions…

Laura Tabellini Pierre / February 8, 2021
cat and dog

Oncology

NanoString Proudly Introduces the new nCounter® Canine IO Panel.

It may have happened to you, as it happened to some of us here at NanoString®: the furry, four-legged trouble-making family member you just can’t stay mad at is sick,…

Laura Tabellini Pierre / January 5, 2021
blue background of cancerous cells

Oncology

From an Egyptian Papyrus to the Hallmarks of Cancer: A Journey through the Development of Knowledge in Oncology Research

The word “cancer” was used for the first time in ancient Greece by Hippocrates, often termed the Father of Medicine for his contributions to modern medical practice. Even prior to…

Laura Tabellini Pierre / September 29, 2020
blue background of cancerous cells

Oncology Q&A

Statistically Significant Results without the Headache. Q&A with Sarah Church, Ph.D., Senior Scientist at NanoString.

Talking to Sarah, whether during social gatherings or within the office walls, is always a pleasure. Dr. Church is a Senior Scientist at NanoString and one of the warmest people…

Laura Tabellini Pierre / July 27, 2020
blue background of cancerous cells

Oncology Q&A

Going Beyond PDL-1. Q&A with Dr. Nina Radosevic- Robin, MD.

Dr. Nina Radosevic-Robin, MD, is a Board-Certified Surgical/Molecular Pathologist at Centre Jean Perrin, a Sr. Scientist within the Unit 1240 of French National Institute for Medical Research (INSERM), and a…

Laura Tabellini Pierre / June 22, 2020